ELIXA

ELIXA came first. After 2008, the FDA required manufacturers to demonstrate that new diabetes drugs did not raise cardiovascular risk, and ELIXA was the first GLP-1 trial completed under that requirement. It enrolled 6,068 adults with type 2 diabetes who had recently had an acute coronary syndrome — a heart attack or unstable angina — and randomized them to lixisenatide or placebo. Pfeffer and colleagues published it in the New England Journal of Medicine in 2015.

Median follow-up was 25 months. A primary endpoint event occurred in 13.4% on lixisenatide and 13.2% on placebo, a hazard ratio of 1.02. Noninferiority was established; superiority was not, with a p-value of 0.81 — about as neutral as a result gets. Hospitalization for heart failure and death rates did not differ either. Lixisenatide was not associated with more serious adverse events, severe hypoglycemia, pancreatitis, pancreatic tumors or allergic reactions.

Two design features probably explain why ELIXA looks different from the trials that followed. Lixisenatide is a short-acting GLP-1 that mainly blunts post-meal glucose spikes rather than providing continuous receptor coverage. And enrolling people within weeks of an acute coronary event, then following them for only two years, is a narrow window in which to show a slow-acting protective effect.

The common confusion is treating ELIXA as evidence against the whole class. It is better read as the trial that set the bar the class was later measured against. LEADER, SUSTAIN-6, REWIND and AMPLITUDE-O cleared it; EXSCEL did not. Lixisenatide is no longer marketed in the United States as a standalone product.

Worth asking your clinician: whether your GLP-1 is a short-acting or long-acting one, and whether the trial evidence behind it applies to your situation. Our ELIXA deep dive and cardiovascular study roundup put the trials in order.